List of Excipients in Branded Drug ONDANSETRON HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing ONDANSETRON HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	ondansetron hydrochloride	0054-0064	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	ondansetron hydrochloride	0054-0064	GLYCERIN
Hikma Pharmaceuticals USA Inc	ondansetron hydrochloride	0054-0064	SACCHARIN SODIUM ANHYDROUS
Hikma Pharmaceuticals USA Inc	ondansetron hydrochloride	0054-0064	SODIUM BENZOATE
Hikma Pharmaceuticals USA Inc	ondansetron hydrochloride	0054-0064	SODIUM CITRATE
Hikma Pharmaceuticals USA Inc	ondansetron hydrochloride	0054-0064	WATER

What are the Most Frequently-Used Excipients in ONDANSETRON HYDROCHLORIDE?

# Of NDCs	Excipient
5	ANHYDROUS CITRIC ACID
94	ANHYDROUS LACTOSE
100	CELLULOSE, MICROCRYSTALLINE
13	CITRIC ACID MONOHYDRATE
1	CROSCARMELLOSE SODIUM
35	FERRIC OXIDE YELLOW

Ondansetron Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Ondansetron hydrochloride is a mature, heavily genericized antiemetic with limited molecule-level exclusivity. Commercial differentiation depends on dosage form, patient usability, supply reliability, preservative strategy, taste masking, and regulatory execution. The strongest opportunities are orally disintegrating tablets, pediatric oral liquids, oral films, ready-to-administer injectable presentations, and excipient systems that improve stability or administration without creating new safety concerns.

What is the market and regulatory status of ondansetron hydrochloride?

Ondansetron hydrochloride is the hydrochloride dihydrate salt of ondansetron, a selective 5-HT3 receptor antagonist. It is approved for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, radiotherapy, and postoperative recovery. The FDA-approved product family includes conventional tablets, orally disintegrating tablets, oral solution, and injection presentations. [1-4]

Attribute	Commercial position
Active ingredient	Ondansetron hydrochloride dihydrate
Pharmacologic class	Selective 5-HT3 receptor antagonist
Reference brand	Zofran
Main dosage forms	Tablets, ODTs, oral solution, injection
Typical oral strengths	4 mg and 8 mg
Typical injectable strength	2 mg/mL
Primary users	Oncology patients, surgical patients, emergency departments, pediatric patients
Regulatory pathway for generics	Abbreviated New Drug Application, or ANDA
Regulatory pathway for differentiated products	505(b)(2), where the formulation or delivery system creates a meaningful distinction
Current exclusivity profile	Mature generic market with no practical molecule-level exclusivity

The commercial market is primarily volume-driven. Hospital contracts, pharmacy-channel substitution, generic price competition, product availability, and dosage-form convenience have greater commercial relevance than the underlying active pharmaceutical ingredient.

What excipients are used in ondansetron hydrochloride products?

The excipient system changes materially by dosage form. FDA labeling and product-specific inactive ingredient records identify several recurring excipient classes. [1-5]

Conventional tablets

Conventional ondansetron tablets commonly use:

• Lactose monohydrate
• Microcrystalline cellulose
• Pregelatinized starch
• Magnesium stearate

This is a conventional immediate-release system. The formulation challenge is not complex drug release. It is achieving acceptable content uniformity, mechanical strength, rapid disintegration, low friability, and low manufacturing cost.

Lactose-free versions may have a commercial advantage for patients with lactose sensitivity, institutional formularies that prefer lactose-free products, or markets where lactose supply is constrained. Suitable alternatives include mannitol, microcrystalline cellulose, dibasic calcium phosphate, starches, and coprocessed excipients.

Orally disintegrating tablets

Brand and generic ondansetron ODT products use excipient systems designed for rapid oral dispersion and palatability. Common components include:

• Mannitol
• Gelatin or alternative binder systems
• Aspartame
• Sodium methylparaben
• Sodium propylparaben
• Flavoring agents
• Superdisintegrants in some generic products

ODT formulations create more formulation value than standard tablets because the product must balance rapid disintegration with adequate tablet strength. Excessive compression can delay disintegration. Insufficient compression can increase breakage during packaging and distribution.

Aspartame creates a labeling consideration for patients with phenylketonuria. A sucralose-, acesulfame potassium-, or steviol-glycoside-based system could remove the phenylalanine warning, subject to taste, stability, and regulatory acceptance.

Oral solutions

Ondansetron oral solutions commonly use:

• Purified water
• Sorbitol or another polyol
• Sodium citrate
• Citric acid
• Flavoring agents
• Preservatives, depending on the formulation

The main formulation risks are precipitation, pH drift, microbial growth, taste, preservative compatibility, and dose measurement. Sorbitol can produce gastrointestinal discomfort at higher exposures and may require specific labeling for patients with hereditary fructose intolerance, depending on the formulation and jurisdiction.

A low-sugar or sugar-free liquid can target pediatric and hospital use. Unit-dose cups or oral syringes can reduce dosing errors and improve administration in children.

Injectable products

Ondansetron hydrochloride injection is typically formulated with:

• Water for injection
• Sodium chloride for isotonicity
• Citric acid monohydrate
• Sodium citrate for buffering and pH control

The injection is an acidic aqueous solution. The formulation strategy must control pH, osmolality, particulate matter, container compatibility, extractables, leachables, and chemical degradation. [3,4]

A preservative-free presentation is commercially useful in neonatal, pediatric, oncology, and hospital settings. Ready-to-administer syringes and premixed infusion bags can reduce manipulation and medication-preparation steps.

What excipient strategy best fits each ondansetron dosage form?

The optimal excipient strategy depends on the target patient, administration environment, and regulatory pathway.

Dosage form	Primary excipient objective	Commercially relevant options
Standard tablet	Low cost and reliable immediate release	Lactose-free filler, direct-compression system, high-throughput coating
ODT	Fast disintegration and acceptable taste	Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, sucralose, flavor systems
Oral solution	Taste, microbial control, dose accuracy	Sorbitol or glycerol, buffered pH, preservative system, unit-dose packaging
Oral film	Thin-film robustness and rapid hydration	Pullulan, hydroxypropyl methylcellulose, maltodextrin, plasticizer, sweetener
Injection	Stability, sterility, low particulate burden	Citrate buffer, sodium chloride, low-sorption container, preservative-free packaging
Premixed infusion	Administration efficiency	Compatible diluent, bag material with low adsorption, ready-to-use labeling

ODT strategy

An ODT product should prioritize:

1. Disintegration in approximately 30 seconds or less.
2. Mechanical durability during blister packaging and shipment.
3. Taste masking without excessive tablet mass.
4. Low moisture uptake.
5. A packaging system that protects the tablet from humidity.

Mannitol is attractive because it provides a cooling mouthfeel and relatively favorable tablet properties. Crospovidone can support rapid water uptake. Low-substituted hydroxypropyl cellulose and croscarmellose sodium are alternative disintegration tools. The final choice depends on compression force, tablet hardness, friability, and moisture sensitivity.

A differentiated ODT could exclude aspartame, lactose, and animal-derived gelatin. This would create a clearer positioning for patients with phenylketonuria, lactose intolerance, vegetarian preferences, or religious dietary requirements.

Pediatric liquid strategy

A pediatric liquid should prioritize dose flexibility, palatability, microbial control, and accurate administration. A unit-dose oral syringe or prefilled oral dosing device can have greater practical value than a novel excipient alone.

Potential design choices include:

• Sugar-free and alcohol-free composition
• Low-viscosity formulation compatible with oral syringes
• Buffered pH to preserve chemical stability
• Preservative system supported by antimicrobial effectiveness testing
• Fruit flavor with low bitterness and low aftertaste
• 1 mg/mL concentration to simplify common pediatric dosing

The formulation must avoid excipient levels that create gastrointestinal, metabolic, or allergy concerns in young children. Pediatric excipient safety is a central regulatory issue, and the FDA has emphasized age-appropriate evaluation of excipient exposure. [6]

Oral film strategy

Ondansetron is a candidate for oral-film development because the dose is low and the product can target patients who have difficulty swallowing tablets or cannot access water.

A practical film platform may use pullulan, hydroxypropyl methylcellulose, maltodextrin, or a combination of film-forming polymers. Plasticizers such as polyethylene glycol or glycerol can improve flexibility. Sweeteners and flavoring agents must address the active ingredient's bitterness without increasing film tackiness or moisture sensitivity.

The primary risks are:

• Dose nonuniformity across the film web
• Film brittleness or curling
• Moisture sensitivity
• Taste persistence
• Packaging cost
• Scale-up from laboratory casting to continuous manufacture

An oral film may fit a 505(b)(2) strategy if the sponsor can support a meaningful clinical or pharmacokinetic distinction. A simple reformulation without a meaningful therapeutic or administration benefit may face limited commercial protection.

What formulation patents protect ondansetron hydrochloride products?

The original ondansetron molecule and early therapeutic uses are long off-patent. The commercial market is therefore open to generic tablets, ODTs, oral liquids, and injections, subject to product-specific regulatory requirements.

Historical patent protection for the original active ingredient and branded product has expired. The principal generic entry pathway is the ANDA, with product-specific patents evaluated through the Orange Book and applicable certification procedures. [7,8]

Later patent opportunities are more likely to concern:

• Specific ODT compositions
• Oral films
• Taste-masking systems
• Stable liquid formulations
• Ready-to-administer injection systems
• Container-closure combinations
• Combination products
• New dosing regimens or clinical uses

A formulation patent must contain technically defensible limitations. Broad claims covering common excipients, routine buffers, or ordinary tablet manufacturing steps are vulnerable to invalidity or design-around arguments.

How strong is the patent estate for ondansetron?

The overall patent estate is weak at the molecule level and potentially moderate for a well-engineered delivery platform.

Patent category	Likely strength
Original compound claims	Expired
Original antiemetic use claims	Expired or commercially ineffective
Conventional tablet excipients	Weak unless tied to a specific performance result
ODT formulation	Moderate if claims define a non-obvious composition and performance
Oral film	Moderate if manufacturing and dose-uniformity claims are narrow but defensible
Pediatric liquid	Low to moderate; strongest where stability and preservative performance are distinctive
Ready-to-administer injection	Moderate if packaging, stability, and administration features are integrated
Manufacturing process	Moderate where the process solves a reproducible scale-up or impurity problem

When did ondansetron lose exclusivity?

Ondansetron's original compound and branded-product exclusivity expired years ago. Generic ondansetron products have been marketed in the United States for many years in multiple dosage forms. The current competitive question is not when the molecule loses exclusivity. It is whether a new dosage form can obtain regulatory differentiation, limited formulation patent protection, or preferred purchasing status.

FDA Orange Book review remains relevant for any specific reference-listed drug and dosage form. Paragraph IV certifications may arise against later-listed formulation or method-of-use patents, but routine generic ondansetron products generally compete in an established off-patent market. [7]

Which companies are challenging ondansetron patents?

The relevant competitive set consists primarily of generic manufacturers and contract manufacturers rather than companies pursuing a molecule-level patent challenge. Generic suppliers have marketed ondansetron products across oral and injectable forms, including products from large generic companies, specialty manufacturers, and hospital-supply providers.

A current litigation list cannot be treated as static because formulation patents, ANDA disputes, and product-specific settlements change by dosage form and reference product. The commercial baseline is that generic entry is established and broad competition exists.

What Paragraph IV risks exist?

A sponsor developing a new ondansetron formulation faces two distinct risks:

1. The sponsor may need to certify against a listed formulation or method-of-use patent for the relevant reference product.
2. A later generic entrant may challenge the sponsor's own formulation patents.

Paragraph IV risk is most relevant for a differentiated product seeking a period of commercial protection. It is less important for a standard immediate-release generic where the core product is already widely available.

A formulation sponsor should expect challenges based on:

• Obviousness over known ODT excipient systems
• Routine substitution of sweeteners or binders
• Lack of unexpected dissolution or stability results
• Inadequate written description of broad excipient ranges
• Non-infringement through alternative polymers, flavors, or packaging

What FDA regulatory strategy fits an ondansetron formulation?

ANDA pathway

An ANDA is appropriate for a conventional generic that matches the reference product in active ingredient, dosage form, strength, route, and relevant performance characteristics. The applicant must establish bioequivalence and comply with current good manufacturing practice requirements.

This is the lowest-risk route for a standard tablet, ODT, oral solution, or injection that closely follows an approved reference product.

505(b)(2) pathway

A 505(b)(2) application may fit a product with a new delivery system, administration method, concentration, or formulation that relies partly on FDA findings for an approved ondansetron product. Potential candidates include:

• Oral film
• Longer-stability liquid
• Premixed injection
• New pediatric concentration
• Device-assisted oral dosing system

The commercial case depends on whether the new product solves a measurable problem. Convenience alone may support market adoption but may not create durable regulatory exclusivity.

What commercial opportunities exist for ondansetron excipient innovation?

Ready-to-administer hospital products

Hospitals can value products that reduce preparation time and medication-error risk. Opportunities include:

• Prefilled syringes
• Small-volume ready-to-use bags
• Standardized concentrations
• Barcode-enabled unit-dose packaging
• Preservative-free single-dose formats

The value proposition is operational. A product that reduces pharmacy compounding or nursing preparation may win contracts even without molecule-level patent protection.

Aspartame-free ODTs

An ODT without aspartame can target patients with phenylketonuria and consumers seeking alternative sweeteners. The product must preserve taste and disintegration performance. This is a differentiated niche rather than a broad exclusivity strategy.

Lactose-free and gelatin-free products

Lactose-free tablets and gelatin-free ODTs can address dietary restrictions and institutional purchasing requirements. These changes are relatively easy to design around, so commercial protection would depend primarily on branding, supply reliability, and channel access.

Pediatric oral liquids

A stable, palatable, alcohol-free oral solution with an integrated oral syringe has broad practical value. Unit-dose packaging can support hospital, emergency department, and outpatient pediatric use.

Oral films

An oral film can target patients with dysphagia, active vomiting, limited access to water, or a need for discreet administration. The main commercial barriers are film manufacturing scale, packaging cost, and taste.

Global low-cost supply

Ondansetron is suitable for high-volume, low-cost production because the active ingredient is established and the dosage forms are technically mature. Competitive advantages can come from:

• Dual-source excipient procurement
• Local packaging
• Reduced tablet weight
• Moisture-resistant blister design
• Regional regulatory dossiers
• Reliable injectable supply

What manufacturing and intellectual-property barriers matter most?

The largest manufacturing barriers are not synthesis of ondansetron. They are formulation consistency, sterile manufacturing, packaging, and supply-chain control.

For oral products, key controls include blend uniformity, assay, degradation products, dissolution, tablet friability, moisture uptake, and flavor consistency. For liquids, the critical controls are pH, preservative effectiveness, microbial limits, fill volume, and dosing-device accuracy. For injections, sterility assurance, endotoxin control, particulate matter, container integrity, and extractables and leachables dominate.

Excipient supply is commercially important. Mannitol, microcrystalline cellulose, crospovidone, flavors, preservatives, and specialized film polymers can become bottlenecks if suppliers are not qualified. A dual-source strategy reduces manufacturing interruption risk but may require bridging data because changes in particle size, grade, moisture, or functionality can alter product performance.

How does ondansetron compare with competing antiemetic opportunities?

Ondansetron has a mature and low-cost profile compared with newer antiemetics such as palonosetron, netupitant combinations, rolapitant, and newer neurokinin-1 receptor antagonists.

Product category	Differentiation potential	Market barrier	Main opportunity
Ondansetron conventional tablet	Low	Low	Cost and supply
Ondansetron ODT	Moderate	Moderate	Taste, rapid disintegration, patient convenience
Ondansetron oral film	Moderate to high	High	Dysphagia and water-free dosing
Ondansetron injection	Moderate	High	Ready-to-administer hospital use
Palonosetron injection	Higher clinical differentiation	Higher	Longer duration and oncology protocols
NK1 antagonist combinations	High	High	Chemotherapy regimen protection
Ondansetron pediatric liquid	Moderate	Moderate	Dosing flexibility and palatability

Ondansetron's advantage is broad familiarity, low active-ingredient cost, and established prescribing behavior. Its disadvantage is limited pricing power and extensive generic competition.

What revenue exposure and generic launch scenarios should investors assess?

Revenue exposure for a new ondansetron product depends on channel and product architecture.

Launch scenario	Price pressure	Adoption driver	Patent dependence
Standard tablet generic	Very high	Lowest acquisition cost	Minimal
ODT generic	High	Patient convenience and formulary preference	Low to moderate
Pediatric liquid	Moderate	Dose flexibility and taste	Moderate
Oral film	Moderate initially	Dysphagia and water-free use	Higher
Prefilled injection	Moderate	Hospital workflow	Moderate
Novel combination product	Variable	Clinical differentiation	High

A generic entrant can launch rapidly where no blocking patent exists and manufacturing capacity is available. A differentiated formulation may require a longer development cycle but can command better pricing if it obtains favorable formulary positioning, device integration, or limited exclusivity.

Key Takeaways

• Ondansetron hydrochloride is a mature generic active ingredient with no meaningful molecule-level exclusivity.
• Excipient strategy is most valuable in ODTs, oral liquids, oral films, and ready-to-administer injections.
• Aspartame-free, lactose-free, gelatin-free, sugar-free, and preservative-free designs provide practical differentiation.
• Pediatric liquids and hospital-ready injectables offer stronger commercial value than another conventional tablet.
• ODT and oral-film patents must rely on specific, non-obvious formulation or manufacturing features.
• FDA ANDA development is appropriate for standard generic products; 505(b)(2) may fit new delivery systems.
• The largest barriers are taste, moisture control, sterile manufacturing, packaging, preservative performance, and supply reliability.
• Commercial success will depend more on contracts, channel access, and product availability than on active-ingredient patent protection.

FAQs

Is ondansetron hydrochloride still patent protected?

The original ondansetron compound and branded-product exclusivity have expired. New protection may exist for specific formulations, delivery systems, manufacturing processes, or uses.

Which excipient is best for ondansetron ODT products?

Mannitol is commonly attractive because it supports palatability and tablet performance. Crospovidone, croscarmellose sodium, or low-substituted hydroxypropyl cellulose may support rapid disintegration, depending on the formulation.

Can an ondansetron oral film obtain FDA approval?

Yes. An oral film may be developed through an ANDA if it meets applicable generic requirements or through a 505(b)(2) application when the formulation or delivery system differs materially from an approved product.

What is the strongest commercial opportunity in ondansetron?

Ready-to-administer hospital injections, pediatric oral liquids, and differentiated ODTs have the clearest commercial rationale. Oral films may offer higher differentiation but involve greater manufacturing and packaging complexity.

Are excipient changes enough to create new market exclusivity?

Usually not. Excipients can support a differentiated product, but durable exclusivity generally requires patent claims directed to a non-obvious formulation, delivery system, manufacturing process, or clinically meaningful use.

References

1. U.S. Food and Drug Administration. (2010). Zofran tablets prescribing information.
2. U.S. Food and Drug Administration. (2010). Zofran orally disintegrating tablets prescribing information.
3. U.S. Food and Drug Administration. (2010). Zofran injection prescribing information.
4. DailyMed. (2024). Ondansetron hydrochloride injection, tablets, and oral solution labeling. U.S. National Library of Medicine.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
6. U.S. Food and Drug Administration. (2016). Demonstration of substantial evidence of effectiveness for human drug and biological products.
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
8. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.